Medication Monitor



Generic Name (Trade Name—Company)
Notes
September 20, 2019

Glucagon injection

(Gvoke—Xeris Pharmaceuticals)
FDA approves first ready-to-use liquid glucagon for severe hypoglycemia

On September 10, Xeris Pharmaceuticals announced FDA approval of glucagon injection for treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and older.

It is the first glucagon product approved that can be administered via a prefilled syringe or auto-injector. It will be available in two doses: a 0.5-mg/0.1-mL dose for pediatric patients and a 1-mg/0.2-mL dose for adolescent and adult patients. 

The product is contraindicated in patients with pheochromocytoma, insulinoma, and patients with a known hypersensitivity to glucagon or to any of the excipients.

The most common adverse reactions are nausea, vomiting, and hypoglycemia.